摘要
新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)爆发以来的临床实践证明,我国的中医药防控措施及中西医结合治疗手段使得疫情得到了有效的控制。截止至2020年3月6日,中医药参与救治确诊病例近6万,治愈出院超2万。在危重期,中药方剂、中成药和药物配伍的使用情况中,人参的使用频率在药物分布中占了56.41%。按照人参复方、人参复方或单方联合抗病毒药物、人参提取物、人参皂苷分类,综述了近30年人参及其皂苷和人参复方在防治病毒性疾病、抗病毒作用及机制等方面的文献报道,旨在为人参及其皂苷在防治新冠肺炎等病毒性疾病方面的开发应用提供科学依据。
Clinical practice since the outbreak of the novel coronavirus disease(COVID-19)has proven that the prevention and control measures of traditional Chinese medicine and the integrated treatment of traditional Chinese and Western medicine in China have effectively controlled the epidemic situation.Up to March 6 in 2020,Chinese medicine participated in the treatment of nearly 60000 confirmed cases,and more than 20000 were cured and discharged.In the critical period,the frequency of use of ginseng in the distribution of prescriptions,Chinese patent medicines and drug compatibility accounted for 56.41%of the drug distribution.According to the classification of ginseng compound,ginseng compound or ginseng single herb integrated with other antiviral drugs,ginseng extract,and ginsenosides,this article reviews the literature reports on ginseng prescriptions,ginseng and its saponins in the prevention and treatment of viral diseases,and related antiviral mechanisms,etc,with view to providing scientific basis for the use of ginseng and its saponins to prevent and treat viral diseases such as novel coronavirus pneumonia.
作者
李雪
时圣明
赵余庆
LI Xue;SHI Sheng-ming;ZHAO Yu-qing(Shenyang Pharmaceutical University,Shenyang 110016,China;Tianjin Institute of Pharmaceutical Research,Tianjin 300301,China;Key Laboratory of Drug Design and Research Based on Target,Ministry of Education,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处
《中草药》
CAS
CSCD
北大核心
2020年第9期2379-2389,共11页
Chinese Traditional and Herbal Drugs
基金
辽宁省发改委创新药物原料工业化制备工程技术中心(2007)。
